Core Viewpoint - Rosen Law Firm is reminding investors who purchased Treace Medical Concepts, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on June 10, 2025 [1]. Group 1: Class Action Details - Investors who purchased Treace Medical securities between May 8, 2023, and May 7, 2024, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting the law firm [3][6]. - The lawsuit claims that Treace Medical made false or misleading statements regarding its business operations and the demand for its primary product, the Lapiplasty 3D Bunion Correction System [5]. Group 2: Legal Representation - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. - The firm has achieved significant settlements in the past, including over $438 million for investors in 2019, and has been recognized for its performance in securities class action settlements [4].

Core Viewpoint - A class action securities lawsuit has been filed against Treace Medical Concepts, Inc. alleging securities fraud that affected investors between May 8, 2023, and May 7, 2024 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Treace Medical Concepts made false statements regarding the impact of competition on the demand for its primary product, the 3D bunion correction system, "Lapiplasty" [2]. - It is alleged that due to competition, Treace Medical's revenue declined, prompting the company to accelerate plans for an alternative product to osteotomy [2]. - The defendants' positive statements about the company's business and prospects were claimed to be materially misleading and lacked a reasonable basis [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until June 10, 2025, to request to be appointed as lead plaintiff [3]. - Participation in the lawsuit does not require serving as a lead plaintiff, and there are no out-of-pocket costs for class members [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Treace Medical Concepts, Inc. regarding a class action lawsuit due to alleged misleading statements and failure to disclose critical information affecting the company's stock value [1][3]. Group 1: Allegations and Impact - The complaint alleges that during the class period from May 8, 2023, to May 7, 2024, Treace Medical faced competition that negatively impacted the demand for its primary product, the 3D bunion correction system known as "Lapiplasty" [1]. - As a result of the competition, Treace Medical's revenue declined, prompting the company to accelerate plans for an alternative product to osteotomy [1]. - The defendants' positive statements regarding the company's business and prospects were claimed to be materially misleading and lacked a reasonable basis [1]. Group 2: Class Action Details - Shareholders who purchased TMCI shares during the specified class period are encouraged to register for the class action, with a deadline set for June 10, 2025 [2]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the status of the case [2]. - There is no cost or obligation for shareholders to participate in the case [2]. Group 3: Law Firm's Mission - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and illegal business practices [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions [3].

All representation is on a contingency fee basis. Shareholders pay no fees or expenses. Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of class actions, the Firm has been named to The National Law Journal's "Plaintiff ...

NEW YORK, May 16, 2025 (GLOBE NEWSWIRE) -- Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international shareholder and consumer rights litigation firm, has filed a securities class action lawsuit in the United States District Court for the Middle District of Florida against Treace Medical Concepts, Inc. (“Treace Medical” or the “Company”) (NASDAQ: TMCI), and certain of its former and current officers and/or directors (collectively, “Defendants”). The Class Action asserts claims under §§10(b) and 20(a ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Treace Medical To Contact Him Directly To Discuss Their OptionsIf you suffered losses exceeding $50,000 in Treace Medical between May 8, 2023, and May 7, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, May 16, 2025 /PRNew ...

Core Viewpoint - A class action securities lawsuit has been filed against Treace Medical Concepts, Inc. due to alleged securities fraud impacting investors between May 8, 2023, and May 7, 2024 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Treace Medical Concepts made false statements regarding the demand for its primary product, the 3D bunion correction system, "Lapiplasty," which was affected by competition [2]. - It is alleged that the company's revenue declined, prompting the need to accelerate plans for an alternative product to osteotomy [2]. - The defendants' positive statements about the company's business and prospects were reportedly misleading and lacked a reasonable basis [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until June 10, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4].

Core Viewpoint - Treace Medical Concepts, Inc. (NASDAQ: TMCI) is facing a class action lawsuit due to allegations of issuing materially false and misleading statements regarding its primary product, the 3D bunion correction system, "Lapiplasty" [3]. Summary by Relevant Sections Class Period and Allegations - The class period for the lawsuit is from May 8, 2023, to May 7, 2024 [3]. - Allegations include that competition negatively impacted the demand for the Lapiplasty system, leading to a decline in Treace Medical's revenue [3]. - The company needed to accelerate plans for an alternative product to osteotomy due to these competitive pressures [3]. - Defendants' positive statements about the company's business and prospects were claimed to be materially misleading and lacked a reasonable basis [3]. Next Steps for Shareholders - Shareholders who purchased TMCI shares during the specified class period are encouraged to register for the class action by June 10, 2025 [4]. - Registration allows shareholders to be enrolled in a portfolio monitoring software for status updates throughout the case [4]. - There is no cost or obligation for shareholders to participate in this case [4]. Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [5].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Treace Medical Concepts, Inc. regarding a class action lawsuit due to alleged misleading statements and failure to disclose critical information during the class period from May 8, 2023, to May 7, 2024 [1] Group 1: Allegations and Impact - The complaint alleges that competition negatively affected the demand and utilization of Treace Medical's primary product, the 3D bunion correction system known as "Lapiplasty" [1] - As a result of the competition, Treace Medical's revenue declined, prompting the company to accelerate plans for an alternative product to osteotomy [1] - The defendants' positive statements about the company's business and prospects were claimed to be materially misleading and lacked a reasonable basis [1] Group 2: Class Action Details - Shareholders who purchased shares of TMCI during the specified class period are encouraged to register for the class action, with a deadline of June 10, 2025, to seek lead plaintiff status [2] - Once registered, shareholders will be enrolled in a portfolio monitoring software to receive updates throughout the case lifecycle [2] - Participation in the case incurs no cost or obligation for the shareholders [2] Group 3: Law Firm's Mission - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors affected by deceit, fraud, and illegal business practices [3] - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions [3]

Group 1 - The class action was filed on behalf of all persons and entities that purchased Treace Medical Concepts, Inc. (TMCI) securities between May 8, 2023, and May 7, 2024 [1] - The company focuses on advancing the standard of care for the surgical management of bunion and related midfoot deformities [1] - Allegations include that Treace Medical misled investors regarding the demand for its primary product, the Lapiplasty 3D Bunion Correction System, and that competition impacted its demand [2] Group 2 - The complaint states that Treace Medical's revenue declined, necessitating an acceleration of plans to offer an alternative product to osteotomy [2] - Following the revelation of these issues, Treace Medical's stock price fell nearly 63%, closing at $4.17 per share on May 8, 2024 [2] - Shareholders interested in serving as lead plaintiff must file their papers with the court by June 10, 2025 [3] Group 3 - Robbins LLP operates on a contingency fee basis, meaning shareholders pay no fees or expenses [4] - The firm has been dedicated to helping shareholders recover losses and improve corporate governance since 2002 [4]